Free Trial
NASDAQ:ARTV

Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis

Artiva Biotherapeutics logo
$11.13 +0.17 (+1.55%)
(As of 09:48 AM ET)

About Artiva Biotherapeutics Stock (NASDAQ:ARTV)

Key Stats

Today's Range
$10.98
$11.21
50-Day Range
$9.80
$15.83
52-Week Range
$9.68
$17.31
Volume
1,399 shs
Average Volume
133,900 shs
Market Capitalization
$270.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.25
Consensus Rating
Buy

Company Overview

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Receive ARTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artiva Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTV Stock News Headlines

Cantor Fitzgerald Estimates ARTV FY2024 Earnings
JD Vance Predicts: Wall Street vs. Trump & Your Money
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy from TD Cowen
See More Headlines

ARTV Stock Analysis - Frequently Asked Questions

Artiva Biotherapeutics' stock was trading at $11.77 at the beginning of 2024. Since then, ARTV stock has decreased by 5.4% and is now trading at $11.13.
View the best growth stocks for 2024 here
.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by $0.24.

Artiva Biotherapeutics (ARTV) raised $167 million in an initial public offering on Friday, July 19th 2024. The company issued 13,920,000 shares at a price of $12.00 per share.

Artiva Biotherapeutics' lock-up period expires on Wednesday, January 15th. Artiva Biotherapeutics had issued 13,920,000 shares in its public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

Artiva Biotherapeutics' top institutional investors include RA Capital Management L.P. (40.57%), Geode Capital Management LLC (1.27%), Samsara BioCapital LLC (1.20%) and Wellington Management Group LLP (0.80%). Insiders that own company stock include Yong-Jun Huh and Global Strategic Fund I Venbio.
View institutional ownership trends
.

Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Artiva Biotherapeutics investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Delcath Systems (DCTH), Advanced Micro Devices (AMD), AngioDynamics (ANGO), Broadcom (AVGO) and Genius Sports (GENI).

Company Calendar

Last Earnings
11/12/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/11/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ARTV
Previous Symbol
NASDAQ:ARTV
Fax
N/A
Employees
81
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.25
High Stock Price Target
$23.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+93.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.28 per share

Miscellaneous

Free Float
N/A
Market Cap
$266.22 million
Optionable
N/A
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:ARTV) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners